| STMicroelectronics N.V.: STMicroelectronics and NUS launch Corporate Lab to power the future of Edge AI in Singapore | STMicroelectronics and NUS launch Corporate Labto power the future of Edge AI in Singapore HELIX joint R&D initiative to enable new generative and embodied AI use cases at the edge through system-to-silicon... ► Artikel lesen |
| AKTIEN IM FOKUS: Chipwerte profitieren dank Coreweave von frischer KI-Fantasie | FRANKFURT (dpa-AFX) - Ein überraschend starker Quartalsbericht von Coreweave sowie ein weit über den Erwartungen liegender Ausblick von Super Micro Computer haben am Mittwoch Aktien aus Europas Halbleiterbranche... ► Artikel lesen |
| ROUNDUP/Aktien Europa Schluss: Rekordhohe Börsen überwiegend leicht im Plus | PARIS/LONDON/ZÜRICH (dpa-AFX) - Die Mehrheit der wichtigsten europäischen Aktienmärkte hat am Montag moderat zugelegt. Angesichts der rekordhohen Börsenstände und der aktuellen Gemengelage hielten... ► Artikel lesen |
| VivoSim Labs, Inc.: VivoSim Provides Financial and Listing Compliance Update | SAN DIEGO, Aug. 06, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the "Company" or "VivoSim"), a provider of next-generation New Approach Methodologies (NAM) 3d human cellular models... ► Artikel lesen |
| VivoSim Labs, Inc.: VivoSim Receives $5M Milestone Payment from Eli Lilly; Provides Guidance That It Expects Revenue Growth of 500%+ in FY2027 | SAN DIEGO, July 15, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the "Company" or "VivoSim"), a provider of next-generation New Approach Methodologies (NAM) 3d human cellular models... ► Artikel lesen |
| VivoSim Labs, Inc.: VivoSim Appoints Arumugham (Ragoo) Raghunathan as Vice President of Global Sales | SAN DIEGO, March 03, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the "Company" or "VivoSim"), a provider of next-generation New Approach Methodologies (NAMs) for preclinical safety... ► Artikel lesen |
| INOVIO Pharmaceuticals, Inc.: INOVIO Reports Second Quarter 2026 Financial Results and Recent Business Highlights | U.S. Food and Drug Administration (FDA) review of Biologics License Application (BLA) for INO-3107 as a treatment for Recurrent Respiratory Papillomatosis (RRP)... ► Artikel lesen |
| Inovio Pharmaceuticals, Inc.: INOVIO Announces Pricing of $20.0 Million Public Offering | PLYMOUTH MEETING, Pa., July 29, 2026 /PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on developing and commercializing... ► Artikel lesen |
| Inovio Pharmaceuticals, Inc.: INOVIO Announces Proposed Public Offering | PLYMOUTH MEETING, Pa., July 29, 2026 /PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on developing and commercializing... ► Artikel lesen |